# Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

> clinical trial · VERIFIED · 2026-06-23

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Recurrent Multiple Myeloma

- Company: National Cancer Institute (NCI)
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT06465316

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.